These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

353 related items for PubMed ID: 22702445

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Evaluating targets and costs of treatment for secondary hyperparathyroidism in incident dialysis patients: the FARO-2 study.
    Roggeri DP, Cozzolino M, Mazzaferro S, Brancaccio D, Paoletti E, Roggeri A, Costanzo AM, di Luzio Paparatti U, Festa V, Messa P.
    Int J Nephrol Renovasc Dis; 2015; 8():1-6. PubMed ID: 25565880
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Cost-effectiveness of cinacalcet hydrochloride for hemodialysis patients with severe secondary hyperparathyroidism in Japan.
    Komaba H, Moriwaki K, Goto S, Yamada S, Taniguchi M, Kakuta T, Kamae I, Fukagawa M.
    Am J Kidney Dis; 2012 Aug; 60(2):262-71. PubMed ID: 22445709
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Effect of paricalcitol on mineral bone metabolism in kidney transplant recipients with secondary hyperparathyroidism.
    Borrego Utiel FJ, Bravo Soto JA, Merino Pérez MJ, González Carmelo I, López Jiménez V, García Álvarez T, Acosta Martínez Y, Mazuecos Blanca MA.
    Nefrologia; 2015 Aug; 35(4):363-73. PubMed ID: 26306956
    [Abstract] [Full Text] [Related]

  • 12. Cost-effectiveness analysis of paricalcitol versus calcitriol for the treatment of SHPT in dialytic patients from the SUS perspective.
    Menezes FG, Abreu RM, Itria A.
    J Bras Nefrol; 2016 Aug; 38(3):313-319. PubMed ID: 27737389
    [Abstract] [Full Text] [Related]

  • 13. Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study.
    Ketteler M, Martin KJ, Wolf M, Amdahl M, Cozzolino M, Goldsmith D, Sharma A, Marx S, Khan S.
    Nephrol Dial Transplant; 2012 Aug; 27(8):3270-8. PubMed ID: 22387567
    [Abstract] [Full Text] [Related]

  • 14. Comparative effectiveness of paricalcitol versus cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis.
    Schumock GT, Walton SM, Lee TA, Marx SE, Audhya P, Andress DL.
    Nephron Clin Pract; 2011 Aug; 117(2):c151-9. PubMed ID: 20699620
    [Abstract] [Full Text] [Related]

  • 15. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L.
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [Abstract] [Full Text] [Related]

  • 16. Paricalcitol treatment of secondary hyperparathyroidism in hemodialysis patients: a German-Austrian, single-arm, open-label, prospective, noninterventional, observational study.
    Biggar P, Kovarik J, Klauser-Braun R, Graf H, Müller HW, Veres A, Seidinger S, Ketteler M.
    Nephron Clin Pract; 2014 Nov; 126(1):39-50. PubMed ID: 24458019
    [Abstract] [Full Text] [Related]

  • 17. Cost per responder analysis in patients with secondary hyperparathyroidism on dialysis treated with cinacalcet.
    Belozeroff V, Lee A, Tseng S, Chiroli S, Campbell JD.
    J Med Econ; 2013 Sep; 16(9):1154-62. PubMed ID: 23869940
    [Abstract] [Full Text] [Related]

  • 18. Paricalcitol- or cinacalcet-centred therapy affects markers of bone mineral disease in patients with secondary hyperparathyroidism receiving haemodialysis: results of the IMPACT-SHPT study.
    Cozzolino M, Ketteler M, Martin KJ, Sharma A, Goldsmith D, Khan S.
    Nephrol Dial Transplant; 2014 Apr; 29(4):899-905. PubMed ID: 24500308
    [Abstract] [Full Text] [Related]

  • 19. Comparison of paricalcitol with maxacalcitol injection in Japanese hemodialysis patients with secondary hyperparathyroidism.
    Akizawa T, Akiba T, Hirakata H, Kinugasa E, Tominaga Y, Fukagawa M, Yokoyama K, Zhang W, Linde PG, Suzuki M.
    Ther Apher Dial; 2015 Jun; 19(3):225-34. PubMed ID: 25363733
    [Abstract] [Full Text] [Related]

  • 20. Chronic kidney disease Markov model comparing paricalcitol to calcitriol for secondary hyperparathyroidism: a US perspective.
    Nuijten M, Andress DL, Marx SE, Sterz R.
    Curr Med Res Opin; 2009 May; 25(5):1221-34. PubMed ID: 19335321
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.